Benitec Biopharma Inc. (BNTC)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Jerel A. Banks M.D., Ph.D.
|
Executive Chairman & CEO | 1.26M | -- | 1975 |
|
Ms. Megan Joan Boston B.Com., C.A.
|
CFO & Secretary | 833.04k | -- | 1972 |
|
Ms. Sophie Mukadam
|
Chief Operating Officer | 870.44k | -- | 1981 |
|
Dr. Michael Graham
|
Head of Discovery & Founding Scientist | 135.96k | -- | -- |
|
Dr. Claudia Kloth Ph.D.
|
Senior Vice President of Manufacturing | -- | -- | -- |
Benitec Biopharma Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 24
Description
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines in the United States. Its Silence and Replace, a DNA-directedRNA interference platform, that combines RNA interference with gene therapy to create medicines which simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene, which is in phase 1b/2a for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Corporate Governance
Upcoming Events
November 12, 2026 at 9:00 PM UTC
Benitec Biopharma Inc. Earnings Date
Recent Events
March 20, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
